Synlogic has been granted a patent for genetically engineered bacteria that produce short-chain fatty acids to attenuate metabolic diseases. The bacteria are designed to respond to specific environmental conditions in the mammalian gut. GlobalData’s report on Synlogic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Synlogic Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Synlogic, Peptide pharmacophores was a key innovation area identified from patents. Synlogic's grant share as of February 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Genetically engineered bacteria for attenuating metabolic diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Synlogic Inc

A recently granted patent (Publication Number: US11896627B2) discloses a bacterium engineered to produce short-chain fatty acids, specifically butyrate, propionate, or acetate, in response to environmental conditions found in the mammalian gut. The bacterium also includes a gene for producing indole-3-acetaldehyde. The patent claims cover various aspects of the engineered bacterium, including the presence of specific promoters induced by low-oxygen or anaerobic conditions, the use of plasmids or chromosomes for gene cassette and promoter placement, and the inclusion of a kill switch or toxic substance gene for safety measures.

Furthermore, the patent extends to a pharmaceutically acceptable composition containing the engineered bacterium and a carrier, formulated for oral administration to treat metabolic diseases or disorders. The specified conditions for treatment include type 1 diabetes, type 2 diabetes, metabolic syndrome, and a range of genetic syndromes affecting metabolism. The composition aims to leverage the engineered bacterium's ability to produce beneficial short-chain fatty acids in response to gut environmental cues to potentially address a variety of metabolic conditions effectively. The patent highlights the potential of probiotic or commensal bacteria, such as Bacteroides, Bifidobacterium, Clostridium, Escherichia, Lactobacillus, and Lactococcus, in therapeutic applications for metabolic disorders.

To know more about GlobalData’s detailed insights on Synlogic, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies